Mucuna pruriens as adjunct therapy to levodopa in advanced Parkinson’s disease

Fernando Botello-Villagrana and Daniel Martinez-Ramirez*
Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, NL, Mexico

Abstract

Background: Parkinson’s disease (PD) is a neurodegenerative disorder whose treatment in advanced stages is often complex and challenging. The treatment goal at this stage is to provide greater clinical stability, with less “off” time and longer “on” time. Mucuna pruriens (MP) is a legume plant traditionally used in Ayurvedic medicine for Parkinsonian-type diseases. This plant contains a diversity of elements, among which levodopa stands out. Objective: We explored the effect of MP as adjunct therapy to levodopa in a PD patient. Methods: We report the case of a 42-year-old woman with PD in advanced stages due to motor fluctuations and dyskinesias. Due to the progression of her disease, the limitations that it generates and the economic inability to opt for other therapies such as surgical treatments, we used MP as an adjunct therapy to levodopa. Results: MP produces a clinical motor effect similar to conventional levodopa. MP shortened the time to reach the “on” state and prolonged this state without exacerbating dyskinesias. Psychiatric side effects were observed only with high dosages of MP. Conclusions: MP shows to be a promising adjunct therapy to levodopa in advanced PD patients without access to other conventional therapies.

Key words: Parkinson’s disease. Mucuna pruriens. Levodopa. Motor fluctuations. Dyskinesia.
Introduction

The management of Parkinson’s disease (PD) in advanced stages is complex. During these stages of the disease, PD patients develop variations in the clinical response (e.g., motor and non-motor fluctuations) and/or involuntary movements induced by the dopaminergic treatment (e.g., dyskinesias). Treatment in these stages should be focused on providing greater clinical stability during their waking hours, resulting in less “off” time and longer “on” time without generating disabling dyskinesias. At present, different pharmacological strategies in addition to the surgical and device-assisted therapies are recommended to increase the stability of levodopa in the brain. However, these therapies are not fully available in some countries or become economically inaccessible for people affected with PD, thus limiting their treatment options in these advanced stages of the disease.

Mucuna pruriens (MP) is a legume plant belonging to the Fabaceae family that grows widely in tropical and subtropical regions of the world, popularly used in traditional Ayurvedic medicine for Parkinson’s-like diseases. MP mainly contains levodopa in addition to other functional components in lesser amounts. Several studies in animals have demonstrated its antioxidant and anti-inflammatory properties suggesting a possible benefit for neurodegenerative diseases such as PD. In this case report, we describe the clinical response to MP as adjunct therapy to levodopa at different dosages as a possible additive for neurodegenerative diseases.

Methods

This is a 42-year-old woman with a diagnosis of PD subtype postural instability with a 6-year history of gait disorder, Hoehn and Yahr Stage 2 in advanced stages due to fluctuations and dyskinesias. In the initial assessment, the patient presents fluctuations with an “on” state delay of approximately 1-2 h and an end of the dose deterioration of 1 h, calculating 50% of the day being in an “off” state, and thus, this condition being disabling for the patient. The duration of the “on” state was 3 h with non-disabling diphasic dyskinesias, calculating 25% of the day in this clinical state. In subsequent visits, treatment was optimized by adjusting the dose and frequency of levodopa to 125 mg every 3 h, adding pramipexole as dopamine agonist in dosage of 3 mg/day divided in three doses, and adding selegiline as monoamine oxidase type B (MAO B) inhibitor at dosages of 10 mg/day. Although proposed, it was not possible for the patient to use a catechol-O-methyl transferase (COMT) inhibitor due to its cost. Due to the clinical progression, advanced therapy options such as surgical or device assisted were considered. However, it is not possible for the patient to consider these options at this moment due to her financial situation. For these reasons and in the presence of disabling fluctuations despite pharmacological optimization, it was decided to start an 8-session trial using MP at different dosages as an adjunct therapy to levodopa in this patient.

Results

Figure 1 shows the time to reach the “on” state and figure 2 shows the duration of the “on” medication state after trying MP with levodopa at different doses. The results show less time to reach the “on” state and longer duration of the “on” state with the combination of MP and levodopa in comparison to levodopa alone. The presence and severity of dyskinesias did not vary with the different doses tested. Regarding the adverse events of using MP, the patient referred feeling nausea as well as confusion and visual hallucinations. These were observed while the patient was at doses of 20 g of MP.

Discussion

In the present case report, we observed the following results: (1) the average time to reach the “on” state was shorter using 20 g versus 10 g of MP (39.7 min vs. 47.3 min); (2) the average duration of the clinical “on” state was greater using 20 g versus 10 g of MP (241.0 min vs. 214.3 min); (3) the time and severity of dyskinesias were similar between both doses of MP; and (4) gastrointestinal and neuropsychiatric adverse effects occurred only in tests using 20 g of MP.

At present, there is scarce literature reporting the use of MP in PD. One of the initial reports was an open study of 60 patients with PD evaluating the clinical effect of MP as monotherapy at 12 weeks of follow-up. Doses of 7.5 g of MP were used per dose, varying from 2 to 5 doses per day depending on the patient’s needs. The authors observed a significant improvement in the motor score of the Unified Parkinson’s Disease Rating Scale (UPDRS) from 18.2 SD 8.1 to 9.8 SD 7.4 and on the Hoehn and Yahr scale from 2.5 SD 1 to 1.6 SD 1. They
observed mild gastrointestinal symptoms in 20% of patients. In another study comprising eight patients with PD, it was observed that 30 g of MP decreased the time to reach the “on” state and prolonged “on” state time by 21.9% significantly compared to standard levodopa/carbidopa. They did not observe differences in dyskinesias or tolerability. In a case report, it was shown a reduction in motor and non-motor fluctuations with a sustained response to 3 months of follow-up using levodopa/benserazide 100/25 mg three tablets daily together with 5 g of MP in five doses a day with a cup of green tea.

Another recent study openly investigated 18 patients with PD analyzing motor changes at 90 and 180 min after administration of the study dose, the duration of the “on” state and adverse effects. The different treatments were used sequentially and randomly, including a dose of dispersible levodopa at a dose of 3.5 mg/kg combined with levodopa/benserazide at a recommended dose; a pharmaceutical preparation of levodopa without a dopa decarboxylase inhibitor, a placebo dose and two doses of MP, one considered high (17.5 mg/kg) and the other low (12.5 mg/kg). The authors observed that low doses of MP showed a similar motor response to levodopa/benserazide dose with fewer dyskinesias and adverse effects, while the MP at high doses showed a greater motor response, longer duration of “on” state, and minor dyskinesias. Fewer adverse effects were also seen with MP compared to levodopa. The most recent study with a 16-week non-inferiority randomized open-label experimental design explored the effect of daily MP consumption versus levodopa/carbidopa in 14 people with PD with motor fluctuations and dyskinesias. A dose of MP was used applying a conversion factor of 3.5-5 times, considering the specific ecotype used of MP whose content is 5.7% of levodopa. The authors observed a longer duration of the “on” state, no differences were observed in dyskinesias, and there was a similar efficacy in quality of life and in non-motor and motor symptoms. Greater gastrointestinal adverse events were observed with MP.

Our patient had similar therapeutic results as previously described in the literature. Based on the current evidence, although limited, it is suggested that MP provides clinical effects on motor symptoms similar to conventional levodopa, shortening the time to reach the “on” state and prolongs the “on” state without evidence of increasing dyskinesias. Similar clinical effects were observed in our patient, shortening the time to reach “on” state. However, there might be a higher frequency of adverse effects with MP, especially gastrointestinal and neuropsychiatric side effects.

Figure 1. Time to reach the “on” state with different doses of levodopa and *Mucuna pruriens*. The greatest benefit was observed while using 62.5 mg of levodopa/carbidopa with 10 g of *Mucuna pruriens*. Adverse effects such as dizziness, nausea, and neuropsychiatric effects were observed using 20 g of *Mucuna pruriens*. The patient did not reach the “on” state at 120 min while using 125 mg of levodopa/carbidopa with 0 g of *Mucuna pruriens* so this trial was suspended.

LC: levodopa/carbidopa; MP: *Mucuna pruriens*; LB: levodopa/benserazide.

Figure 2. “On” state duration with different doses of levodopa and *Mucuna pruriens*. The greatest duration of the “on” state can be observed when the patient used the combination of 125 mg of levodopa/carbidopa with 20 g of *Mucuna pruriens*, providing an “on” state of 320 min; at 20 g of *Mucuna pruriens*, the patient reported nausea and dizziness. Trial with 125 mg of levodopa/carbidopa with 0 g of *Mucuna pruriens* was suspended because the patient could not reach the on state.

LC: levodopa/carbidopa; MP: *Mucuna pruriens*; LB: levodopa/benserazide.
MP is a seed with a diverse content of elements, including phytates, tannins, saponins, alkaloids, and levodopa. The content of this last element varies with the MP ecotype, with a broad range concentration (from 1.2% to 9.5%), estimating an average of 5.3%; this fact denotes the importance of knowing levodopa’s concentration in the MP ecotype that is being used to avoid adverse effects. MP has shown in clinical studies an improvement in Parkinsonian characteristics with a decrease in dyskinesias, as well as a reduction in the time to reach the “on” state and an increase on the “on” state time without presenting serious adverse effects, especially when consuming a dose >30 g. This pharmacological profile observed in MP and, specifically, the benefit it provides in relation to control motor fluctuations is possibly due to a better levodopa pharmacokinetic profile attributed to some of the more than 50 constituents identified to date in MP. The mechanisms that allow this have not been established since the analysis of each of the elements that constitute MP, although feasible, is expensive and time consuming. However, genistein or its precursor, genistein contained in the MP seed, has been proposed as elements with a possible dopa decarboxylase inhibitor activity that improves levodopa’s pharmacokinetic profile contained in MP.

Some of the limitations of the present work were the inability to determine the percentage of levodopa content in MP used as well as the lack of standardization of the dosages and the bioavailability of MP or any other information regarding its pharmacokinetic profile. However, this therapeutic modality represents an alternative due to its low cost and high availability when compared to standard pharmacological treatment. Furthermore, the use of recommended therapies in these stages of the disease such as deep brain stimulation, due to their high cost, is often not feasible for patients, thus limiting the possibility of adequately controlling the symptoms and, therefore, the quality of life of patients. This opens the opportunity to continue the investigation of MP as a pharmacological therapy in PD in better designed clinical studies allowing the expansion of the scientific knowledge of its use.

Conclusions

Our observations suggest that MP produces a clinical effect similar to conventional levodopa, shortening the time to reach the “on” state and prolonging the “on” time without exacerbating dyskinesias. Greater gastrointestinal and neuropsychiatric adverse effects are likely to occur with high dosages of MP.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest

The authors declare no conflicts of interest.

Ethical disclosures

Protection of human and animal subjects. The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

References